TRASTUZUMAB DERUXTECAN

Brand name:

• Enhertu®

Pharmaceutical company:

AstraZeneca Pty Ltd

Condition/indication:
(therapeutic use)

• Human epidermal growth factor receptor 2 (HER2)-low breast cancer

PBAC Submission type:

New listing (Early Re-entry Pathway)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – March 2024

Related medicines:

• TRASTUZUMAB DERUXTECAN

Submission received for:

March 2024 PBAC meeting

Opportunity for consumer comment:

Open 22/11/2023 and close 31/01/2024 (see PBS Website)

PBAC meeting:

Held on 13/03/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

12/04/2024

Lodgement of required documentation:

19/04/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 14/05/2024

Status:

Finalised

Government processes:

Commenced on 24/05/2024

Medicine listed on the PBS:

01/09/2024 (see PBS schedule)

---